Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2012

Lu Hailing, Dietsch Gregory N, Matthews Maura-Ann H, Yang Yi, Ghanekar Smita, Inokuma Margaret, Suni Maria, Maino Vernon C, Henderson Katherine E, Howbert James Jeffry, Disis Mary L, Hershberg Robert M

Abstract excerpt

PURPOSE: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation of natural killer (NK) cells. EXPERIMENTAL DESIGN: HEK-TLR transfectants were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoquinolines
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibody-Dependent Cell Cytotoxicity

Share to Benzazepines

Share to Drug Synergism

Share to Interleukin-12

Share to Rituximab

Share to Toll-Like Receptor 8

Source

Identifiers

PMID: 22128302
DOI: 10.1158/1078-0432.CCR-11-1625

Genes

TLR8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22128302-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.PMID 22128302Read ↗

CD20‐Specific Immunoligands Engaging NKG2D Enhance γδ T Cell‐Mediated Lysis of Lymphoma CellsSemantic proximity Read ↗

Adjuvant and immunomodulatory potential of <i>in vivo</i> Natural Killer T (NKT) activation by NKTT320Semantic proximity Read ↗

The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsSemantic proximity Read ↗

Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca2+ mobilization and cytotoxicity in human NK cells.Semantic proximity Read ↗

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Semantic proximity Read ↗

High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19Semantic proximity Read ↗

Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.Semantic proximity Read ↗

VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cellsSemantic proximity Read ↗

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.Semantic proximity Read ↗

Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy.Semantic proximity Read ↗

HLA-E-VL9 antibodies enhance NK cell and CD8 <sup>+</sup> T cell cytotoxicity against HIV-infected CD4 <sup>+</sup> T cellsSemantic proximity Read ↗

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.